Tech Company Financing Transactions
RaNA Therapeutics Funding Round
On 1/18/2012, RaNA Therapeutics announced $20.7 million in Series A funding from SR One Capital Management, Atlas Venture and Monsanto.
Transaction Overview
Company Name
Announced On
1/18/2012
Transaction Type
Venture Equity
Amount
$20,700,000
Round
Series A
Investors
SR One Capital Management (Lead Investor) (Brian Gallagher)
Atlas Venture (Jean-François Formela)
Proceeds Purpose
The Series A funds will be used to accelerate R&D efforts across a range of disease areas, expand RaNA's broad IP estate in the field of long non-coding RNA, and expand the core team.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Sidney St. 310
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
RaNA Therapeutics is a biotechnology company using its proprietary RNA upregulation platform to discover and develop highly selective epigenetic modulators of gene expression. RaNA's technology upregulates the expression of desirable genes that can prevent or treat disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ronald Renaud
VP - Bus. Development
Brian Fenton
Browse more venture capital transactions:
Prev: 1/18/2012: Nexenta Systems venture capital transaction
Next: 1/18/2012: Carticept Medical venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs